ipeptidyl peptidase-4 (DPP-4) inhibitors and is the first member of its class to be approved at one dosage strength (5 mg, once daily). With Tradjenta, no dose adjustment is recommended for patients with kidney or liver impairment. Tradjenta is a tablet that can be taken with or without food. Tradjenta lowers blood sugar in a glucose-dependent manner by increasing incretin levels, which increase insulin levels after meals and throughout the day
Tradjenta Patient Information
Read this Patient Information before you start taking Tradjenta and each time you get a refill. There may be new information. This information does not take the place of talking to your doctor about your medical condition or your treatment.
What is Tradjenta?
•Tradjenta is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
•Tradjenta is not for people with type 1 diabetes.
•Tradjenta is not for people with diabetic ketoacidosis (increased ketones in the blood or urine).
•It is not known if Tradjenta is safe and effective when used with insulin.
•It is not known if Tradjenta is safe and effective in children.
Home › Drugs by Condition › D › Diabetes, Type 2 › Tradjenta Consumer Information
Print | Save or Share Tradjenta
Generic Name: linagliptin
Date of Approval: May 2, 2011
Company: Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company
Treatment for: Type 2 Diabetes
Ads by Google
Diabetic Diet & Meals
www.diabetesinfocenter.orgFree Diabetic Recipes > Breakfast, Lunch - Snack - Dinner - Dessert.
Statin Drug Side Effects
www.healthy-heart-guide.comYour doctor might not be aware of the dangers of cholesterol drugs!
Glucobetic > Guaranteed
www.nutritionupdate.infoMost Advanced Formula > It Works Maintain Healthy Blood Sugar
FDA Approves Tradjenta
Related Video
Diabetes
Why managing blood sugar is so important.
.The U.S. Food and Drug Administration (FDA) has approved Tradjenta (linagliptin) tablets, a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. Tradjenta can be used as monotherapy or in combination with other commonly prescribed medications for type 2 diabetes — metformin, sulfonylurea or pioglitazone — and demonstrated reductions in hemoglobin A1C (HbA1C or A1C) levels up to 0.7 percent (compared to placebo). A1C is measured in people with diabetes to provide an index of blood sugar control for the previous two to three months. Tradjenta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine). It has not been studied in combination with insulin.
Tradjenta belongs to a class of prescription medications called dipeptidyl peptidase-4 (DPP-4) inhibitors and is the first member of its class to be approved at one dosage strength (5 mg, once daily). With Tradjenta, no dose adjustment is recommended for patients with kidney or liver impairment. Tradjenta is a tablet that can be taken with or without food. Tradjenta lowers blood sugar in a glucose-dependent manner by increasing incretin levels, which increase insulin levels after meals and throughout the day.
Tradjenta Patient Information
Read this Patient Information before you start taking Tradjenta and each time you get a refill. There may be new informa |
